Clinicians have a new line of weapons in their arsenal to treat recurring nasal polyps. Over the past year several new monoclonal antibody-based biologic drugs have been approved to treat the ...

Approval based on WAYPOINT Phase III results demonstrating reduced nasal polyp severity and nasal congestion, near-elimination of the need for surgery and significantly reduced systematic ...

WILMINGTON, DE — AstraZeneca and Amgen have received U.S. Food and Drug Administration (FDA) approval for TEZSPIRE® (tezepelumab-ekko) as an add-on maintenance treatment for adults and adolescents ...

TUESDAY, Oct. 28, 2025 (HealthDay News) -- The U.S. Food and Drug Administration approved Tezspire (tezepelumab-ekko; Amgen) for the add-on maintenance treatment of inadequately controlled chronic ...

Sanofi and Regeneron’s Dupixent (dupilumab) could be set for its ninth US approval after the drug met all the primary and secondary endpoints in a Phase III study in allergic fungal rhinosinusitis ...

Company plans new, confirmatory Phase 3 clinical trial of LYR-210 for treatment of chronic rhinosinusitis (CRS) without nasal polyps, on path to NDA submission – WATERTOWN, Mass., Nov. 12, 2025 (GLOBE ...

Amgen (AMGN) is a top biotech value pick with strong sales, robust R&D, and resilient growth. Read here for an analysis of ...

Jefferies London Healthcare Conference 2025 November 18, 2025 3:30 AM ESTCompany ParticipantsWilliam Lewis - President, CEO ...

Nvidia is the largest company in the world, with a market cap of $5.03 trillion. It's followed by Apple ($3.99 trillion), Microsoft ($3.84 trillion), Alphabet ($3.43 trillion), and Amazon ($2.71 ...

LONDON (AP) — The largest-ever exhibition of the late Queen Elizabeth II’s fashion, including the opulent gowns she wore for her wedding and coronation, will go on display at Buckingham Palace next ...